Approval · Notice of Compliance 14679 · 2013
LEVEMIR: Notice of Compliance 14679
Issued August 23, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14679
- Date
- August 23, 2013
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: levemir (insulin detemir) is indicated for the treatment of adult patients with type 2 diabetes mellitus in combination with victoza (liraglutide) and metformin when victoza and metformin do not achieve adequate glycemis control
- Therapeutic class
- Antidiabetic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LEVEMIR | Not yet assigned | — |
Medicinal ingredients
- INSULIN DETEMIR 100 UNIT per ML